

John M Lachin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2316927/publications.pdf>

Version: 2024-02-01

255
papers

64,943
citations

3933

88
h-index

751

250
g-index

278
all docs

278
docs citations

278
times ranked

43763
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. <i>Journal of Diabetes Investigation</i> , 2022, 13, 125-133.	2.4	21
2	Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002667.	2.8	12
3	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 585-593.	8.6	1
4	Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 659-665.	8.6	14
5	Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2405-e2416.	3.6	9
6	Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications. <i>American Journal of Cardiology</i> , 2022, 174, 158-165.	1.6	1
7	Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 509-518.	11.4	19
8	Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 1779-1787.	8.6	7
9	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes. <i>Ophthalmology</i> , 2021, 128, 554-560.	5.2	4
10	Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108591.	2.8	9
11	Association of Baseline Characteristics With Insulin Sensitivity and β -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	8.6	16
12	OGTT Glucose Response Curves, Insulin Sensitivity, and β -Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β -Cell Function. <i>Diabetes Care</i> , 2021, 44, 817-825.	8.6	20
13	Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	42
14	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1309-1316.	8.6	4
15	Cost-efficient clinical studies with continuous time survival outcomes. <i>Statistics in Medicine</i> , 2021, 40, 3682-3694.	1.6	0
16	Association of glycemia with insulin sensitivity and β -cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107912.	2.3	5
17	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1499-1505.	8.6	20
18	Hyperglucagonemia Does Not Explain the β -Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. <i>Diabetes Care</i> , 2021, 44, 1961-1969.	8.6	9

#	ARTICLE	IF	CITATIONS
19	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 436-445.	11.4	56
20	The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2225-2230.	8.6	21
21	Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). <i>Diabetes Care</i> , 2021, 44, 2216-2224.	8.6	37
22	Shape of the OGTT glucose response curve: relationship with β -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002264.	2.8	12
23	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	3.1	46
24	Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. <i>PLoS ONE</i> , 2021, 16, e0257154.	2.5	11
25	Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. <i>Journal of the American Heart Association</i> , 2021, 10, e022922.	3.7	8
26	Closed testing of each group versus the others combined in a multiple group analysis. <i>Clinical Trials</i> , 2020, 17, 77-86.	1.6	1
27	Withdrawal of medications leads to worsening of <sc>OGTT</sc> parameters in youth with impaired glucose tolerance or <sc>recentlyâ€‘diagnosed</sc> type 2 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 1437-1446.	2.9	7
28	Worst-Rank Score Methodsâ€‘A Nonparametric Approach to Informatively Missing Data. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1670.	7.4	3
29	DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. <i>Nature Metabolism</i> , 2020, 2, 744-762.	11.9	53
30	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 2478-2484.	8.6	19
31	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. <i>Diabetes</i> , 2020, 69, 2440-2445.	0.6	2
32	The minimum intensity of a mixed exposure that increases the risk of an outcome. <i>Statistics in Medicine</i> , 2020, 39, 4016-4024.	1.6	0
33	Nonparametric Statistical Analysis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2080.	7.4	11
34	Models to Assess the Association of a Semiquantitative Exposure With Outcomes. <i>American Journal of Epidemiology</i> , 2020, 189, 1573-1582.	3.4	2
35	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291â€‘299. <i>Diabetes</i> , 2020, 69, e7-e8.	0.6	3
36	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , 2020, 69, 1000-1010.	0.6	106

#	ARTICLE	IF	CITATIONS
37	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2020, 43, 867-874.	8.6	61
38	Risk Factors for Hearing Impairment in Type 1 Diabetes. Endocrine Practice, 2019, 25, 1243-1254.	2.1	5
39	Closed testing using surrogate hypotheses with restricted alternatives. PLoS ONE, 2019, 14, e0219520.	2.5	1
40	Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes, 2019, 68, 1853-1860.	0.6	15
41	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861.	4.5	37
42	Association of Habitual Daily Physical Activity With Glucose Tolerance and β -Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2019, 42, 1521-1529.	8.6	9
43	Lack of Durable Improvements in β -Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2019, 42, 1742-1751.	8.6	56
44	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 1284-1289.	8.6	42
45	Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care, 2019, 42, 883-890.	8.6	76
46	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 875-882.	8.6	114
47	The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes. JACC: Cardiovascular Imaging, 2019, 12, 1341-1349.	5.3	47
48	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care, 2019, 42, 657-664.	8.6	32
49	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664. Diabetes Care, 2019, 42, e137-e137.	8.6	0
50	Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. PLoS ONE, 2019, 14, e0210367.	2.5	13
51	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology, 2019, 7, 128-139.	11.4	223
52	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME [®] trial. European Heart Journal, 2018, 39, 363-370.	2.2	199
53	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 364-367.	2.8	35
54	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	8.6	59

#	ARTICLE	IF	CITATIONS
55	Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	5
56	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. <i>Diabetes Care</i> 2017;40:655â€“662. <i>Diabetes Care</i> , 2018, 41, e64-e64.	8.6	3
57	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
58	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	8.6	534
59	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	1.6	28
60	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , 2018, 41, 2495-2501.	8.6	27
61	Impact of Insulin and Metformin Versus Metformin Alone on Î²-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1717-1725.	8.6	112
62	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. <i>Diabetes Care</i> , 2018, 41, 1696-1706.	8.6	127
63	Properties of composite time to first event versus joint marginal analyses of multiple outcomes. <i>Statistics in Medicine</i> , 2018, 37, 3918-3930.	1.6	3
64	What are the clinical, quality-of-life, and cost consequences of 30â€“years of excellent vs. poor glycemic control in type 1 diabetes?. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 911-915.	2.3	26
65	University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). <i>Clinical Trials</i> , 2018, 15, 366-385.	1.6	0
66	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves Î²-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1917-1925.	8.6	114
67	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018, 41, 1887-1894.	8.6	104
68	Optimal screening schedules for disease progression with application to diabetic retinopathy. <i>Biostatistics</i> , 2018, 19, 1-13.	1.5	9
69	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2017, 40, 777-783.	8.6	141
70	Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 1507-1516.	27.0	101
71	Refining Measurement of Hemoglobin A1c. <i>Clinical Chemistry</i> , 2017, 63, 1433-1435.	3.2	2
72	Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2017, 40, 1010-1016.	8.6	108

#	ARTICLE	IF	CITATIONS
73	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	2.0	112
74	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 793-799.	8.6	18
75	Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2017, 40, 405-411.	8.6	38
76	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , 2017, 40, e165-e166.	8.6	2
77	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	8.6	60
78	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	2.7	12
79	The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. <i>Diabetologia</i> , 2017, 60, 2084-2091.	6.3	62
80	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000461.	2.8	9
81	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	8.6	49
82	Probabilistic measures of cost-effectiveness. <i>Statistics in Medicine</i> , 2016, 35, 3976-3986.	1.6	2
83	Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Journal of the American Heart Association</i> , 2016, 5, e002882.	3.7	18
84	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	6.1	196
85	Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3002-11.	7.1	179
86	Haptoglobin 2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1577-1584.	2.3	20
87	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	4.5	93
88	Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 30.	6.8	19
89	Fallacies of last observation carried forward analyses. <i>Clinical Trials</i> , 2016, 13, 161-168.	1.6	174
90	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	27.0	2,809

#	ARTICLE	IF	CITATIONS
91	Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. Biostatistics, 2016, 17, 178-187.	1.5	77
92	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2016, 374, 1092-1094.	27.0	208
93	Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. PLoS ONE, 2016, 11, e0159958.	2.5	15
94	Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovascular Diabetology, 2015, 14, 118.	6.8	46
95	Data sharing is desirable, but benefits should not be exaggerated. BMJ, The, 2015, 351, h5508.	6.0	1
96	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242.	27.0	2,188
97	Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes. Clinical Trials, 2015, 12, 627-633.	1.6	25
98	Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA - Journal of the American Medical Association, 2015, 313, 45.	7.4	369
99	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA [®]). Diabetes and Vascular Disease Research, 2015, 12, 164-174.	2.0	197
100	Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes. New England Journal of Medicine, 2015, 372, 1722-1733.	27.0	86
101	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	27.0	8,841
102	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 108-114.	2.3	26
103	Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes, 2015, 64, 989-998.	0.6	43
104	Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes. Diabetes, 2015, 64, 266-278.	0.6	115
105	Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. Diabetes, 2015, 64, 631-642.	0.6	261
106	Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different Scales. PLoS ONE, 2014, 9, e108784.	2.5	27
107	Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2014, 37, 39-43.	8.6	173
108	Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. Statistics in Medicine, 2014, 33, 1288-1306.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME [®] , [†]). Cardiovascular Diabetology, 2014, 13, 102.	6.8	198
110	Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study. Diabetes, 2014, 63, 282-290.	0.6	186
111	Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes. Diabetes, 2014, 63, 1748-1762.	0.6	208
112	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818.	6.1	40
113	Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. Diabetes, 2014, 63, 739-748.	0.6	201
114	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350.	6.1	76
115	Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression. PLoS ONE, 2014, 9, e113948.	2.5	1
116	Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model. Statistics in Medicine, 2013, 32, 220-229.	1.6	7
117	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research, 2013, 10, 289-301.	2.0	132
118	Validity of Self-Report in Type 1 Diabetic Subjects for Laser Treatment of Retinopathy. Ophthalmology, 2013, 120, 2580-2586.	5.2	9
119	The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 141-149.	2.3	46
120	Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. Statistics in Medicine, 2013, 32, 4413-4425.	1.6	13
121	Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. Diabetes, 2013, 62, 3976-3986.	0.6	215
122	Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC. Diabetes, 2013, 62, 3561-3569.	0.6	38
123	Reminiscences of Jerry Cornfield. Clinical Trials, 2013, 10, 337-339.	1.6	0
124	Aortic Distensibility in Type 1 Diabetes. Diabetes Care, 2013, 36, 2380-2387.	8.6	23
125	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2013, 36, 2254-2261.	8.6	217
126	Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes, 2013, 62, 3218-3223.	0.6	36

#	ARTICLE	IF	CITATIONS
127	Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes. Diabetes Care, 2013, 36, 2423-2429.	8.6	30
128	Fall in C-Peptide During First 2 Years From Diagnosis. Diabetes, 2012, 61, 2066-2073.	0.6	270
129	High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation, 2012, 27, 1416-1423.	0.7	37
130	Relation Between Carotid Intima-Media Thickness and Left Ventricular Mass in Type 1 Diabetes Mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). American Journal of Cardiology, 2012, 110, 1534-1540.	1.6	8
131	Pilot Genome-Wide Association Search Identifies Potential Loci for Risk of Erectile Dysfunction in Type 1 Diabetes Using the DCCT/EDIC Study Cohort. Journal of Urology, 2012, 188, 514-520.	0.4	18
132	Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4780-4788.	3.6	55
133	The Department of Statistics at The George Washington University. , 2012, , 65-76.		0
134	Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. Journal of Urology, 2011, 185, 1828-1834.	0.4	80
135	Effect of rituximab on human in vivo antibody immune responses. Journal of Allergy and Clinical Immunology, 2011, 128, 1295-1302.e5.	2.9	91
136	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine, 2011, 365, 2366-2376.	27.0	507
137	Levels of Oxidized LDL and Advanced Glycation End Products-Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes. Diabetes, 2011, 60, 582-589.	0.6	82
138	Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis, 2011, 214, 462-467.	0.8	43
139	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes, 2011, 12, 85-90.	2.9	12
140	Power and sample size evaluation for the Cochran-Mantel-Haenszel mean score (Wilcoxon rank) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	24
141	Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus. Circulation, 2011, 124, 1737-1746.	1.6	80
142	Effects of Rosiglitazone, Glyburide, and Metformin on β -Cell Function and Insulin Sensitivity in ADOPT. Diabetes, 2011, 60, 1552-1560.	0.6	208
143	Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin. Clinical Chemistry, 2011, 57, 286-290.	3.2	50
144	Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2011, 60, 607-613.	0.6	109

#	ARTICLE	IF	CITATIONS
145	Increased T Cell Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. Journal of Immunology, 2011, 187, 1998-2005.	0.8	65
146	Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria_{title}An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort_{title}_{title}Microalbuminuria Outcomes in Type 1 Diabetes</sub>. Archives of Internal Medicine, 2011, 171, 412.	3.8	298
147	Gaps in the Glycation Gap Hypothesis. Clinical Chemistry, 2011, 57, 150-152.	3.2	26
148	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1032-1040.	4.5	64
149	Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes. PLoS ONE, 2011, 6, e26471.	2.5	37
150	DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. Current Diabetes Reports, 2010, 10, 276-282.	4.2	108
151	Relationship of myocardial scar with cardiovascular disease risk factors in the diabetes control and complications trial (DCCT)/epidemiology of diabetes interventions and complications (EDIC) study. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
152	Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 2010, 33, 177-183.	8.6	40
153	Failure to Preserve β -Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New-Onset Type 1 Diabetes. Diabetes Care, 2010, 33, 826-832.	8.6	140
154	A Genome-Wide Association Study Identifies a Novel Major Locus for Glycemic Control in Type 1 Diabetes, as Measured by Both A1C and Glucose. Diabetes, 2010, 59, 539-549.	0.6	103
155	Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?. Diabetes Care, 2010, 33, 2719-2721.	8.6	17
156	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2010, 33, 1536-1543.	8.6	257
157	Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1235-1242.	4.5	46
158	Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care, 2010, 33, 1090-1096.	8.6	315
159	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142.	3.6	164
160	Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. American Journal of Clinical Nutrition, 2009, 89, 518-524.	4.7	128
161	Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Clinical Trials, 2009, 6, 565-573.	1.6	21
162	Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes. Diabetes, 2009, 58, 2588-2595.	0.6	92

#	ARTICLE	IF	CITATIONS
163	Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus. <i>Circulation</i> , 2009, 119, 2886-2893.	1.6	271
164	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , 2009, 10, 97-104.	2.9	160
165	Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. <i>New England Journal of Medicine</i> , 2009, 361, 2143-2152.	27.0	900
166	Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. <i>Statistics in Medicine</i> , 2008, 27, 2509-2523.	1.6	50
167	Type 1 Diabetes TrialNet—An International Collaborative Clinical Trials Network. <i>Annals of the New York Academy of Sciences</i> , 2008, 1150, 14-24.	3.8	92
168	Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited. <i>Diabetes</i> , 2008, 57, 995-1001.	0.6	432
169	Rosiglitazone-Associated Fractures in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 845-851.	8.6	498
170	A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2008, 31, 528-533.	8.6	98
171	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β -Cell Function in Therapeutic Trials in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1966-1971.	8.6	250
172	Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants Are Associated With the Development and Progression of Diabetic Nephropathy. <i>Diabetes</i> , 2008, 57, 218-228.	0.6	89
173	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2008, 168, 1867.	3.8	98
174	Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus. <i>JAMA Ophthalmology</i> , 2008, 126, 1707.	2.4	301
175	Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2007, 30, 2453-2457.	8.6	479
176	Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. <i>Diabetes</i> , 2007, 56, 1153-1159.	0.6	84
177	The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2007, 30, 2107-2112.	8.6	68
178	The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial. <i>Diabetes</i> , 2007, 56, 1913-1921.	0.6	57
179	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. <i>Hepatology</i> , 2007, 3, 209-220.	7.3	32
180	A composite design for transition from a preliminary to a full-scale study. <i>Statistics in Medicine</i> , 2007, 26, 5014-5032.	1.6	3

#	ARTICLE	IF	CITATIONS
181	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine, 2006, 355, 2427-2443.	27.0	2,714
182	Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes. Diabetes, 2006, 55, 2357-2364.	0.6	169
183	Operating characteristics of sample size re-estimation with futility stopping based on conditional power. Statistics in Medicine, 2006, 25, 3348-3365.	1.6	12
184	The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2006, 55, 3556-3565.	0.6	238
185	Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes. Diabetes Care, 2006, 29, 2102-2107.	8.6	1,050
186	Parametric survival models for interval-censored data with time-dependent covariates. Biostatistics, 2006, 7, 599-614.	1.5	72
187	Early Termination of the Diabetes Control and Complications Trial. , 2006, , 93-108.		0
188	A review of methods for futility stopping based on conditional power. Statistics in Medicine, 2005, 24, 2747-2764.	1.6	186
189	Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine, 2005, 353, 2643-2653.	27.0	4,433
190	Maximum information designs. Clinical Trials, 2005, 2, 453-464.	1.6	7
191	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.. Diabetes Care, 2005, 28, 233-233.	8.6	11
192	The Society for Clinical Trials supports United States legislation mandating trials registration. Clinical Trials, 2004, 1, 417-420.	1.6	7
193	The role of measurement reliability in clinical trials. Clinical Trials, 2004, 1, 553-566.	1.6	199
194	Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. Obesity, 2004, 12, 1426-1434.	4.0	470
195	Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Statistics in Medicine, 2004, 23, 1519-1521.	1.6	10
196	Over-ruling a group sequential boundary? a stopping rule versus a guideline. Statistics in Medicine, 2003, 22, 3347-3355.	1.6	13
197	Group sequential large sample T2-like tests for multivariate observations. Statistics in Medicine, 2003, 22, 3357-3368.	1.6	1
198	Intensive Diabetes Therapy and Carotid Intima-media Thickness in Type 1 Diabetes Mellitus. New England Journal of Medicine, 2003, 348, 2294-2303.	27.0	761

#	ARTICLE	IF	CITATIONS
199	Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters. Communications in Statistics Part B: Simulation and Computation, 2003, 32, 619-639.	1.2	3
200	Costs Associated With the Primary Prevention of Type 2 Diabetes Mellitus in the Diabetes Prevention Program. Diabetes Care, 2003, 26, 36-47.	8.6	322
201	A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25, 1737-1743.	8.6	215
202	Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine, 2002, 346, 393-403.	27.0	16,031
203	Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. New England Journal of Medicine, 2002, 346, 1685-1691.	27.0	793
204	Application of robust estimating equations to the analysis of quantitative longitudinal data. Statistics in Medicine, 2001, 20, 3411-3428.	1.6	11
205	Statistical Considerations in the Intent-to-Treat Principle. Contemporary Clinical Trials, 2000, 21, 167-189.	1.9	543
206	A Flexible Stochastic Curtailing Procedure for the Log-Rank Test. Contemporary Clinical Trials, 2000, 21, 428-439.	1.9	11
207	Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. New England Journal of Medicine, 2000, 342, 381-389.	27.0	1,460
208	Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials. Contemporary Clinical Trials, 1999, 20, 408-422.	1.9	140
209	Link-Based Models for Survival Data with Interval and Continuous Time Censoring. Biometrics, 1997, 53, 1199.	1.4	39
210	GROUP SEQUENTIAL MONITORING OF DISTRIBUTION-FREE ANALYSES OF REPEATED MEASURES. Statistics in Medicine, 1997, 16, 653-668.	1.6	14
211	Distribution-Free Marginal Analysis of Repeated Measures. Drug Information Journal, 1996, 30, 1017-1028.	0.5	8
212	Martingales without tears. Lifetime Data Analysis, 1995, 1, 361-375.	0.9	4
213	Nonparametric test of stochastic ordering for multiple longitudinal measures. Journal of Biopharmaceutical Statistics, 1995, 5, 235-243.	0.8	3
214	Sequential Monitoring of Survival Data with the Wilcoxon Statistic. Biometrics, 1995, 51, 1175.	1.4	21
215	Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. Cancer Treatment and Research, 1995, 75, 203-223.	0.5	8
216	Natural history and course of acquired lactic acidosis in adults. American Journal of Medicine, 1994, 97, 47-54.	1.5	194

#	ARTICLE	IF	CITATIONS
217	Severe hypoglycaemia in Diabetes Control and Complications Trial. Lancet, The, 1994, 343, 1097-1098.	13.7	1
218	Use of spending functions for occasional or continuous monitoring of data in clinical trials. Statistics in Medicine, 1993, 12, 2219-2231.	1.6	25
219	The use of response-adaptive designs in clinical trials. Contemporary Clinical Trials, 1993, 14, 471-484.	1.9	92
220	A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults. New England Journal of Medicine, 1992, 327, 1564-1569.	27.0	312
221	A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis. New England Journal of Medicine, 1992, 326, 1373-1379.	27.0	459
222	Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations. Biometrics, 1992, 48, 1033.	1.4	41
223	Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Statistics in Medicine, 1992, 11, 1151-1170.	1.6	105
224	Power and sample size evaluation for the mcnemar test with application to matched case-control studies. Statistics in Medicine, 1992, 11, 1239-1251.	1.6	57
225	Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. Contemporary Clinical Trials, 1992, 13, 62-79.	1.9	26
226	Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. Biometrics, 1990, 46, 759.	1.4	69
227	Permutation tests following restricted randomization procedures. Contemporary Clinical Trials, 1990, 11, 150-152.	1.9	0
228	Remembrances of Max Halperin. Statistics in Medicine, 1990, 9, 863-870.	1.6	2
229	Interim analyses with repeated measurements in a sequential clinical trial. Biometrika, 1990, 77, 359-364.	2.4	51
230	Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations. Biometrics, 1988, 44, 513.	1.4	22
231	Properties of randomization in clinical trials: Foreword. Contemporary Clinical Trials, 1988, 9, 287-288.	1.9	13
232	Statistical properties of randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 289-311.	1.9	186
233	Properties of simple randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 312-326.	1.9	144
234	Properties of permuted-block randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 327-344.	1.9	256

#	ARTICLE	IF	CITATIONS
235	Properties of the urn randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 345-364.	1.9	277
236	Randomization in clinical trials: Conclusions and recommendations. Contemporary Clinical Trials, 1988, 9, 365-374.	1.9	236
237	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. Journal of the American Statistical Association, 1988, 83, 339-347.	3.1	119
238	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. Journal of the American Statistical Association, 1988, 83, 339.	3.1	28
239	External monitoring of a data coordinating center: Experience of the national cooperative gallstone study. Contemporary Clinical Trials, 1987, 8, 1-11.	1.9	14
240	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification. Biometrics, 1986, 42, 507.	1.4	343
241	Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Statistics in Medicine, 1986, 5, 73-83.	1.6	37
242	Major issues in the organization and implementation of the national cooperative Gallstone Study (NCGS). Contemporary Clinical Trials, 1984, 5, 1-12.	1.9	3
243	Effects of dose relative to body weight in the national cooperative gallstone study: A fixed-dose trial. Contemporary Clinical Trials, 1983, 4, 125-131.	1.9	3
244	Central laboratory quality control in the national cooperative gallstone study. Contemporary Clinical Trials, 1983, 4, 101-123.	1.9	11
245	The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—Two views. Gastroenterology, 1983, 84, 644-648.	1.3	9
246	National Cooperative Gallstone Study. Gastroenterology, 1982, 82, 638-646.	1.3	82
247	Pretreatment Biliary Lipid Composition in White Patients with Radiopaque Gallstones in the National Cooperative Gallstone Study. Gastroenterology, 1982, 83, 738-752.	1.3	107
248	A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients with Cholelithiasis: The National Cooperative Gallstone Study. Hepatology, 1982, 2, 187S-201S.	7.3	51
249	Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. Biometrics, 1981, 37, 87.	1.4	12
250	Introduction to sample size determination and power analysis for clinical trials. Contemporary Clinical Trials, 1981, 2, 93-113.	1.9	897
251	Sample Size Determinations for $r \times c$ Comparative Trials. Biometrics, 1977, 33, 315.	1.4	58
252	Phasic Heart Rate Responses: Different Patterns in Black and in White Newborns. Psychosomatic Medicine, 1975, 37, 326-332.	2.0	4

#	ARTICLE	IF	CITATIONS
253	On Stepwise Discriminant Analyses Applied to Physiologic Data. Psychophysiology, 1974, 11, 703-709.	2.4	31
254	On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables. Biometrics, 1973, 29, 551.	1.4	9
255	Depression as a symptom of alcoholism: Search for a phenomenon.. Journal of Abnormal Psychology, 1968, 73, 195-197.	1.9	55